骨质疏松症
医学
重症监护医学
生物信息学
病理
生物
作者
Barbara C. Silva,John P. Bilezikian
标识
DOI:10.1146/annurev-med-061709-145401
摘要
Although safe and effective agents are currently available to treat osteoporosis, fragility fractures remain a significant problem worldwide. Recent improvements in the understanding of the cellular, biochemical, and molecular pathways of bone biology have led to the development of newer agents to treat osteoporosis, which may lead to further improvements in outcomes. In this review, we summarize the most recent advances in the field, including new modes of administration of existing drug classes, various approaches to combination therapy, and drugs with novel mechanisms of action to treat osteoporosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI